Ticagrelor Alone Versus Ticagrelor Plus Aspirin After a Heart Attack Treated With Medicine
Compares ticagrelor alone with ticagrelor plus aspirin in adults after a medically treated heart attack.
Plain-language title generated from the registry record
Registry title: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 3
Where in Canada
- Montreal Heart InstituteMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Montreal Heart Institute
- Trial code
- NCT07257198
- Record updated
- 10 March 2026
- Original description
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.Read full original descriptionShow less
Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Inclusion: Age ≥18 years; Hospitalized for type 1 MI, according to the 4th Universal Definition of MI; Coronary angiogram performed; Planned for medical management alone, without revascularization; Willingness to participate and to attend study visits; Expected life expectancy ≥12 months.
Exclusion: Concomitant indication for chronic oral anticoagulant; Concomitant non-coronary indication for dual antiplatelet therapy; Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician; Previous hospitalization for MI, PCI, or CABG within 12 months; Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI; Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.); Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor; Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel; Confirmed or suspected spontaneous coronary artery dissection; Unsuitability for either randomization treatment, based on the judgement of the treating physician.